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Lung cancer is the most common solid tumor in critically ill can-
cer patients admitted to intensive care units and is associated with a 
poor prognosis. Crizotinib is an anaplastic lymphoma kinase (ALK) 
inhibitor, which is active for advanced non–small cell lung cancer 
(NSCLC) patients harboring ALK rearrangements. We report three 
cases of NSCLC patients who required mechanical ventilation for 
respiratory failure and were successfully weaned from mechanical 
ventilation after treatment with ALK inhibitors. These responses 
were accompanied by minimal toxicities and an overt improvement 
in performance status. These results suggest that ALK inhibitors may 
be safe and effective in critically ill patients on mechanical ventila-
tion for respiratory failure resulting from EML4-ALK translocated 
NSCLC progression.
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ventilation, Weaning.
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Lung cancer is the most common solid tumor in critically ill cancer patients with cancer- or treatment-related complica-
tions admitted to intensive care units (ICUs).1 The most com-
mon reason for ICU admission in these patients is respiratory 
failure, necessitating mechanical ventilation.2 Despite recent 
improvements in the intensive care of critically ill cancer 
patients, the outcome of patients with lung cancer admitted 
to the ICU is poor, especially in those requiring mechanical 
ventilation as a result of respiratory failure.1
Crizotinib is an orally active, small-molecule tyrosine 
kinase inhibitor of anaplastic lymphoma kinase (ALK), and it 
has efficacy for non–small-cell lung cancer (NSCLC) with echi-
noderm microtubule-associated protein-like4 - anaplastic lym-
phoma kinase (EML4-ALK) rearrangements. Treatment with 
crizotinib resulted in a rapid and dramatic response with few 
instances of major toxicity,3 enabling its safe administration as 
a salvage treatment for patients with poor performance status. 
Here, we report three Korean ALK-positive NSCLC patients 
with respiratory failure caused by lung cancer progression, who 
were successfully treated with crizotinib during mechanical ven-
tilatory care.
Case 1
A 40-year-old nonsmoker woman had been diagnosed with 
adenocarcinoma of the lung with multiple metastases in both the 
lung and the liver in April 2010. Analysis of the EGFR and KRAS 
genes did not indicate any mutation. She did not respond to com-
bined chemotherapy involving pemetrexed and cisplatin, and she 
was referred to our hospital in July 2010 and erlotinib treatment 
was initiated for her rapidly progressing disease.
After 1 week, she was hospitalized because of respiratory 
failure and progression of bilateral infiltrates on chest 
radiographs. Empirical antibiotics for suspected pneumonia 
were initiated, but oxygenation continued to worsen. She was 
subsequently transferred to the ICU and was intubated 2 days 
later, but she required both a high fraction of inspired oxygen 
(FiO
2
) and elevated positive end-expiratory pressure. However, 
her refractory hypoxemia and hypercapnia persisted, and she 
failed to respond to conventional mechanical ventilation using 
inhaled nitric oxide even after her pneumonia symptoms 
improved. In the absence of evidence of another cause, the 
progression of bilateral infiltrates on chest radiography led us 
to conclude that the advancing lung cancer was responsible for 
the hypoxemia and hypercapnia. Immunohistochemical (IHC) 
staining for ALK protein was positive, but fluorescence in 
situ hybridization analysis could not be performed because of 
insufficient amounts of tumor tissue. Crizotinib was initiated 
21 days after intubation for mechanical ventilation (August 
24, 2010) that was administered in powdered form through 
a feeding tube. Two days after the initiation of crizotinib, 
ventilation had improved enough to correct hypercapnia. Ten 
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days after treatment initiation, oxygenation had improved 
enough to taper out inhaled nitric oxide doses and to reduce 
FiO
2
. The progressive bilateral infiltrates seemed to undergo 
amelioration as well (Fig. 1). During the second treatment 
cycle, that is, on the 25th day of treatment, weaning from 
mechanical ventilation was attempted for the first time. She 
was eventually weaned from mechanical ventilation entirely 
on the 42nd day and was weaned from tracheostomy on the 
57th day of treatment. She recovered fully and was discharged 
60 days after the initiation of crizotinib.
Her response persisted for 84 days until the fifth cycle 
of treatment, when multiple brain metastases were diagnosed. 
Eventually, she died because of rapidly progressing brain 
metastases.
Case 2
A 44-year-old nonsmoking woman was diagnosed with 
adenocarcinoma of the lung with intraabdominal lymph node 
metastases in May 2010. EGFR and KRAS gene analysis 
revealed wild-type genes. After failure to respond to four lines 
of palliative chemotherapy (pemetrexed with cisplatin, erlo-
tinib, gemcitabine, and vinorelbine with cisplatin), she was 
admitted to our hospital because of rapidly progressive dys-
pnea with extensive consolidation in both the lungs. On July 
10, 2011, intubation and mechanical ventilation were initiated 
for respiratory failure. Infectious bronchoalveolar lavage did 
not reveal any microbial growth, and therefore, lung cancer 
progression was suspected as the main cause of respiratory 
failure. A transbronchial lung biopsy was performed, and IHC 
staining results were positive for ALK protein in the cyto-
plasm (Fig. 2). Crizotinib was initiated on July 21, 2011. At 
that time, her arterial oxygen saturation (SaO
2
) was approxi-
mately 87% to 90%, with an oxygen supply of FiO
2
 1.0. After 
1 week, FiO2 was reduced to 0.5. On the 20th day of treatment 
(Fig. 3), the patient was completely weaned from the mechani-
cal ventilator and was weaned from tracheostomy on the 36th 
day of treatment. A chest computed tomography scan after one 
cycle (August 10, 2011) revealed that the multiple metastatic 
lesions in the lung had greatly reduced. Therefore, she was 
discharged from the hospital on the 38th day of treatment, and 
the response was maintained until April 4, 2012, which indi-
cates a progression-free survival of 8 months.
Case 3
A 49-year-old nonsmoking woman was diagnosed 
with stage IV adenocarcinoma of the lung in October 2010. 
Gene sequencing revealed that both the EGFR and KRAS 
genes were of the wild type. One year since her diagnosis, 
all three lines of palliative chemotherapy (gemcitabine 
with cisplatin, pemetrexed with afatinib, and gefitinib) and 
palliative radiotherapy for cervical and mediastinal metastatic 
lymphadenopathy had failed. The IHC staining indicated 
positive results for ALK protein; however, the EML4-ALK 
FIGURe 1.  Chest radiographs before and after crizotinib treatment in case 1.
FIGURe 2.  Positive immunohistochemical staining for ana-
plastic lymphoma kinasein the cytoplasm of lung cancer cells 
(NCL-ALK [clone 5A4], Novocastra, United Kingdom).
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fluorescence in situ hybridization analysis did not give a clear 
result. On November 12, 2011, intubation was performed, 
and mechanical ventilation was initiated for upper airway 
obstruction. On the next day, bilateral vocal cord paresis with 
paradoxical vocal cord movement caused by mediastinal lymph 
nodes metastasis was noted, and tracheostomy was performed 
on the fifth day of initial intubation. An attempt to wean through 
a T-piece failed because of carbon dioxide retention. Crizotinib 
was initiated on November 21, 2011 through a feeding tube. 
On the 10th day of treatment, the patient was transferred to a 
general ward and was placed a mobile ventilator, and on the 
17th day of treatment, complete weaning from the ventilator 
was achieved. On the 31st day of treatment (December 21, 
2011), a chest computed tomography scan revealed a partial 
response to multiple cervical, axillary, and mediastinal 
metastatic lymphadenopathy (Fig. 4). In March 2012 (cycle 
5, day 1), although the removal of the tracheostomy tube still 
could not be attempted because of persistent saliva aspiration 
and a glottis gap, no evidence of lung cancer progression was 
observed. Therefore, she was discharged from the hospital. 
Further information on this patient’s progress is unavailable 
because she was lost to follow-up.
DIsCUssION
Although the main reasons for admission to the ICU 
are treatment related and other complications associated with 
cancer, some patients are admitted to the ICU for chemother-
apy because of cancer-related, life-threatening conditions.4–6 
However, the decision to initiate chemotherapy in critically 
ill cancer patients is extremely complex because the expected 
outcomes or prognostic factors are unclear. Only a few stud-
ies describing the benefits of administrating chemotherapy to 
critically ill cancer patients4–6 have been reported. Moreover, 
respiratory failure requiring mechanical ventilation was sig-
nificantly associated with a poor outcome.4–6 However, most 
patients included in these studies had hematologic malignan-
cies. Therefore, a decision to start chemotherapy for advanced 
solid cancer in the ICU generally carries reluctance because 
of two reasons. First, solid malignancies, including lung can-
cer, are usually less sensitive to chemotherapeutic drugs than 
FIGURe 3.  Chest radiographs before 
and after crizotinib treatment in case 2.
FIGURe 4.  Response to crizotinib in 
case 3. A chest wall metastatic mass 
and malignant pleural effusion on the 
right side reduced after 1 month of 
treatment.
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hematologic malignancies were. Second, poor performance 
status of the Eastern Cooperative Oncology Groups 3 and 4 is 
usually considered a contraindication of cytotoxic chemother-
apy. Cytotoxic chemotherapeutic agents invariably have tox-
icities, including myelosuppression, resulting in an increased 
risk of infection, which in turn is thought to be associated with 
poor outcome, particularly in patients with poor performance 
status.
recently various types of molecularly targeted agents 
have been developed. In many cases the response to these 
agents can be predicted through genetic analysis, and the 
profiles of major adverse events are significantly different 
from those of cytotoxic chemotherapeutic agents, among 
which myelosuppression is less common. Therefore, these 
molecularly targeted agents can be considered for use in cancer 
patients with poor performance status, even when patients are 
receiving critical care because of cancer progression-induced 
organ failure.
In this report, three critically ill patients with metastatic 
NSCLC who required mechanical ventilation for respiratory 
failure in the ICU were treated with crizotinib and were suc-
cessfully weaned from mechanical ventilation. This report 
gives an insight into successful chemotherapy with a molecu-
larly targeted agent in the ICU. Although we have reported 
only three cases, this study is noteworthy because mechani-
cal ventilation is strongly associated with increased hospital 
mortality in lung cancer cases,7 and all the patients in the 
present case study experienced respiratory failure caused by 
heavily pretreated lung cancer progression. Thus, the present 
cases can be a reference in reappraisal and decision making 
for lung cancer patients requiring ICU care because of cancer 
progression.
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